Stability Testing of Drug Products

Scientific Criteria, guidelines and official state requirements in Europe, Japan and USA

Edited by Dr. Wolfgang Grimm,
Dr. Karl Thomae GmbH, D-Biberach

International APV Symposium
on Stability Testing of Pharmaceutical Products,
Munich, December 2–4, 1985

Organized by
Dr. P. Fischer, CH-Bern
Prof. Dr. H. Feltkamp, Bayer AG, D-Leverkusen
Dr. W. Grimm, Dr. Karl Thomae GmbH, D-Biberach
Prof. Dr. H. Sucker, Sandoz AG, CH-Basel

with 104 figures and 8 tables
Contents

Address of the authors: ......................................................... 12

Introduction (W. Grimm) ....................................................... 13

I. Physico-chemical changes from a molecular-galenical view point
   (R. Hüttenrauch) ............................................................ 17
   1. Introduction .................................................................. 17
   2. Solid and semi-solid dosage forms, solids in suspensions ....... 21
   3. Liquid dosage forms ..................................................... 32
   4. Final remarks ................................................................ 39

II. Physicochemical Criteria for semi-solid dosage forms
   (S.S. Davis) ...................................................................... 40
   1. Introduction .................................................................. 40
   2. The various types of semi-solid forms ......................... 40
      2.1 Suspensions ............................................................ 40
      2.2 Emulsions ............................................................... 41
      2.3 Suppositories ........................................................ 41
      2.4 Gels .................................................................... 41
      2.5 Ointments and creams ............................................ 41
   3. Evaluation of physicochemical properties ..................... 42
      3.1 Crystalline properties .............................................. 43
      3.2 Sedimentation and creaming ................................. 43
      3.3 Consistency ........................................................... 44
   4. Accelerated tests .......................................................... 50
   5. Predictive methods ....................................................... 51
   6. Protocols for the evaluation of physical stability .......... 53
   7. Stability limits and conclusions ..................................... 54

III. Physico-chemical Criteria for the stability and stability
     forecast of solid dosage forms (M. Baltezor) .................... 57
     1. Introduction .............................................................. 57
     2. Sensory properties ..................................................... 58
     3. Hardness ................................................................. 58
     4. Retained moisture ....................................................... 59
5. Disintegration .......................................................... 61
6. Dissolution .......................................................... 61
7. Conclusions ......................................................... 63

IV. Changes in medicinal products and the consequences for their therapeutic application (A. Verain) ............................................. 64
1. Introduction .......................................................... 64
2. Notation of stability .................................................. 64
3. Stability and production ............................................. 66
3.1 The formulation process ........................................... 67
3.1.1 Structural changes ............................................. 67
3.1.2 Reactivity ....................................................... 69
3.1.3 Sensibility to humidity ....................................... 69
3.2 Production .......................................................... 70
3.2.1 Polymorphism .................................................. 70
3.2.2 Reactivity ........................................................ 71
3.2.3 Humidity ........................................................ 71
3.2.4 Mechanical manipulation .................................... 72
4. Medicinal accidents due to faulty fabrication techniques or instabilities .................................................. 72
4.1 Incidents independent of the chemical structure of the active molecule .............................................. 72
4.2 Incidents related to the active molecule ....................... 74
5. Conclusions ......................................................... 76

V. Japanese Guideline for Stability Testing (T. Nagai) ............................................. 77
1. Introduction .......................................................... 77
2. Cooperative investigation on the establishment of the method for stability test for pharmaceutical preparations .................................. 78
3. General matters concerning the data of stability testing to be submitted when applying for approval to manufacture (or import) new drugs .............................................. 79
4. Standards for stability testing of new drugs (March 31, 1980) .......................................................... 80
5. Accelerated test standards ........................................... 82
6. Additional Guideline concerning the standards for stability testing of new drugs (June 8, 1984) ........................................... 83

VI. Proposed FDA Guideline for Stability Testing (R. C. Shultz) ............................................. 86
1. Introduction .......................................................... 86
2. Drug substance ...................................................... 87
3. Drug product ........................................................ 89
3.1 Statistical evaluation of an expiration dating period .......... 90
3.2 Design consideration for longterm studies under ambient conditions ........................................... 91
3.2.1 Selection of the batches ........................................... 91
3.2.2 Number of batches ........................................... 91
3.2.3 Selection of samples ........................................... 91
3.2.4 Testing sequence ........................................... 92
4. General product information ........................................... 94
5. Specifications and test methodology information ........................................... 95
6. Study design and study conditions ........................................... 95
7. Stability data information ........................................... 95
8. Data analysis and conclusions ........................................... 96

VII. State of the official regulations concerning stability testing of pharmaceutical products in the EEC (B. Huyghe) ........................................... 97
1. Official regulations concerning stability testing of Belgium ........................................... 97
2. General introduction ........................................... 97
3. What can be said about in raw materials ........................................... 98
4. What can be said in 1985 about medicinal products in pharmaceutical form ........................................... 99
4.1 Acceptability of accelerated testing ........................................... 99
4.2 Number of batches required to perform the stability tests ........................................... 99
4.3 Number of temperatures required in stability tests ........................................... 100
4.4 Desirability to require stability tests in a high humidity atmosphere and/or in the presence of sufficient light ........................................... 101
5. Conclusions ........................................... 101

VIII. Requirements of the Licensing Authority of the Federal Republic of Germany concerning the Stability Testing of Drug Products, with special reference to Phytopharmaceuticals (F.W. Hefendehl) ........................................... 104
1. Stability Tests according to the draft of a Drug Testing Guideline, Section dealing with Quality ........................................... 104
2. General requirements of stability tests ........................................... 104
2.1 Number of batches to be tested ........................................... 105
2.2 Duration of testing ........................................... 105
2.3 Equivalence of tests that were carried out under other conditions ........................................... 105
2.4 Testing frequency ........................................... 106
2.5 Test parameters ........................................... 106
2.6 Stability specificity ........................................... 106
2.7 Stability overages ........................................... 106
3. Foreign documentation and responsibility of the Pharmaceutical Manufacturer ........................................... 107
XI. Stability and Stability Testing of Medicinal Products

APV Guideline and Commentary

1. APV Guideline
   1.1 Application and purpose
   1.2 Definition of stability
      1.2.1 Content of active ingredient
      1.2.2 Purity, degradation products
      1.2.3 Organoleptic, physico-chemical and microbiological characteristics
   1.3 Stability overage
   1.4 Storage time, shelf life
   1.5 Storage conditions
      1.5.1 Normal storage conditions
      1.5.2 Defined storage conditions
   1.5.3 Labelling
   1.6 Packaging
   1.7 Stability Testing
      1.7.1 Container and closure
      1.7.2 Accelerated studies
      1.7.3 Long term studies
         1.7.3.1 Storage conditions for long term studies
         1.7.3.2 Duration of studies
         1.7.3.3 Testing intervals
         1.7.3.4 Test criteria
         1.7.3.5 Test methods
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.7.4</td>
<td>On-going stability</td>
<td>144</td>
</tr>
<tr>
<td>2.</td>
<td>Commentary on the APV Guideline (W. Grimm)</td>
<td>144</td>
</tr>
<tr>
<td>2.1</td>
<td>Stability and stability testing of medicinal products</td>
<td>144</td>
</tr>
<tr>
<td>2.2</td>
<td>Definition of stability</td>
<td>145</td>
</tr>
<tr>
<td>2.2.1</td>
<td>Active ingredient</td>
<td>145</td>
</tr>
<tr>
<td>2.2.2</td>
<td>Purity, degradation products</td>
<td>146</td>
</tr>
<tr>
<td>2.2.3</td>
<td>Organoleptic, physico-chemical and microbiological characteristics</td>
<td>146</td>
</tr>
<tr>
<td>2.3</td>
<td>Stability overage</td>
<td>146</td>
</tr>
<tr>
<td>2.4</td>
<td>Stability period, shelf life</td>
<td>146</td>
</tr>
<tr>
<td>2.5</td>
<td>Storage conditions</td>
<td>147</td>
</tr>
<tr>
<td>2.6</td>
<td>Packaging</td>
<td>148</td>
</tr>
<tr>
<td>2.7</td>
<td>Stability testing</td>
<td>148</td>
</tr>
<tr>
<td>2.7.1</td>
<td>Accelerated stability tests</td>
<td>148</td>
</tr>
<tr>
<td>2.7.2</td>
<td>Long term studies</td>
<td>149</td>
</tr>
<tr>
<td>2.7.3</td>
<td>On-going Studies</td>
<td>150</td>
</tr>
<tr>
<td>XII.</td>
<td>APV Guideline: Stability and Stability testing. State of the art in the</td>
<td>151</td>
</tr>
<tr>
<td></td>
<td>field of stability and stability testing (W. Oeser)</td>
<td></td>
</tr>
<tr>
<td>XIII.</td>
<td>Stability Testing in Industry (W. Grimm)</td>
<td>157</td>
</tr>
<tr>
<td></td>
<td>1. Introduction</td>
<td>157</td>
</tr>
<tr>
<td></td>
<td>2. Content of stability tests</td>
<td>158</td>
</tr>
<tr>
<td></td>
<td>3. Description of the individual phases in a stability testing programme</td>
<td>159</td>
</tr>
<tr>
<td></td>
<td>3.1 Tests with the drug substance</td>
<td>159</td>
</tr>
<tr>
<td></td>
<td>3.2 Screening during pharmaceutical development</td>
<td>160</td>
</tr>
<tr>
<td></td>
<td>3.3 Accelerated studies with the chosen formulation</td>
<td>161</td>
</tr>
<tr>
<td></td>
<td>3.4 Long term testing</td>
<td>162</td>
</tr>
<tr>
<td></td>
<td>3.5 Follow-up studies</td>
<td>165</td>
</tr>
<tr>
<td></td>
<td>3.6 Tests after alterations to routine production</td>
<td>166</td>
</tr>
<tr>
<td></td>
<td>4. Critical assessment of stability test programmes</td>
<td>167</td>
</tr>
<tr>
<td></td>
<td>5. Cooperation with the Authorities</td>
<td>168</td>
</tr>
<tr>
<td></td>
<td>6. The future of stability testing</td>
<td>169</td>
</tr>
<tr>
<td>XIV.</td>
<td>Analytical methods of Stability Testing for chemically defined substances (S. Ebel)</td>
<td>171</td>
</tr>
<tr>
<td></td>
<td>1. Introduction</td>
<td>171</td>
</tr>
<tr>
<td></td>
<td>2. High pressure liquid chromatography</td>
<td>171</td>
</tr>
<tr>
<td></td>
<td>3. Thin layer chromatography</td>
<td>176</td>
</tr>
<tr>
<td></td>
<td>4. UV-spectrometry</td>
<td>180</td>
</tr>
<tr>
<td></td>
<td>5. Voltammetry</td>
<td>182</td>
</tr>
<tr>
<td></td>
<td>6. Titration procedures</td>
<td>183</td>
</tr>
<tr>
<td></td>
<td>7. Conclusions</td>
<td>184</td>
</tr>
</tbody>
</table>
XV. Analytical procedures for stability testing of phytopharmaka and pharmaceutical products derived from natural compounds  
(G. Harnischfeger) ........................................ 188
1. Introduction ........................................... 188
2. General requirements ................................. 189
3. Procedure for the planning of a stability test .... 190
3.1 Predictable chemical change ......................... 192
3.1.1 Redox reactions .................................. 193
3.1.2 Interconversions .................................. 193
3.1.3 Hydrolysis ......................................... 194
3.1.4 Condensations and polymerisations .............. 194
3.1.5 Isomerisations .................................... 195
3.1.6 Photochemical processes ......................... 195
3.2 Predictable galenical changes ....................... 196
4. Technical limitations in stability testing of phytopharmaka 198
5. Methods and their limitations ......................... 198
6. Combination products ................................ 203
7. Examples ................................................ 204
8. Final remarks ........................................... 208

XVI. Stability Testing during development (K. Krummen) .......... 210
1. Introduction ........................................... 210
2. Drug substance reactivities ............................ 211
3. Excipient compatibility ................................ 212
4. Formulation comparison ................................ 215
5. Stability of proposed product ......................... 220
6. Conclusions ............................................. 226

XVII. Packaging materials and shelf life (D. Herrmann) ............ 227
1. Introduction, General remarks ........................ 227
2. Permeation, Plastic bottles ............................ 229
3. Lyophilisates/Freeze-drying stoppers ................. 230
4. Glass .................................................. 230
5. Light protection ....................................... 233
6. Elastomeres/Rubber materials ........................ 235
7. Plastics/General categories ............................ 238
8. Collapsible tubes/Aluminium .......................... 238
9. Conclusions summary ................................... 239